Bioventus CEO Moves to Integra LifeSciences as President of Orthopedics

Integra LifeSciences Holdings Corp. has hired Mark Augusti as a corporate vice president (CVP) and president of the company’s Orthopedics and Tissue Technologies businesses—a new framework for the Plainsboro, N.J.-based company.

Prior to joining Integra, Augusti served as CEO of Durham, N.C.-based Bioventus—a biotechnology spin-off from Smith & Nephew.

Augusti will manage the firm’s Spine and Extremities divisions, including strategic direction, portfolio management and evaluation of corporate development opportunities.

“I am pleased that Mark has become a member of our team,” said Peter Arduini, Integra’s president and CEO. “With more than 25 years of experience in orthopedics, in particular, extremities and biologics, Mark brings a depth of general management experience and leadership that will be instrumental to our growth strategy.”

The creation of the integrated Orthopedics and Tissue Technologies group will increase the effectiveness and capabilities of the combined division to fund the highest priority investments and fuel growth, according to a statement released by the company.

“I am looking forward to becoming a part of Integra’s team to lead the Orthopedics and Tissue Technologies business and advance our growth strategy forward,” said Augusti. “We have an opportunity to bring a business to scale in a dynamic market and to commercialize exciting new
technologies in extremities, wound care, orthobiologics and spine.”

Reporting to Augusti will be Brian Larkin, CVP and president of Spine & Orthobiologics, who will continue to manage the Spine division; Bob Paltridge, who will take on a new role as CVP, president of the company’s Advanced Wound Care division, focusing on the diabetic foot ulcer market; Bill Weber, general manager, of marketing and product development, Extremities; Paul Gonsalves, senior vice president of enterprise sales and corporate marketing; Christian Kelly, senior director, global quality assurance, regulatory affairs and clinical; Nick Gallucci, vice president of U.S. extremities sales.

Augusti has more than 25 years of knowledge and experience in medical technology management His experience in orthopedics, specifically spine, biologics, trauma and extremities, “makes him uniquely qualified to lead Integra’s new division and strengthen its executive leadership bench,” Arduini said.

Prior to his time with Bioventus, Augusti spent nine years with Smith & Nephew in a series of leadership roles, most recently as president of Smith & Nephew’s Biologic Division, where he was appointed to lead Smith & Nephew’s new biologics initiative (which became Bioventus). He also served as president of Smith & Nephew’s president of the Orthopedic Trauma and Clinical Therapies business and senior vice president and general manager of the Trauma business. Prior to that, he spent 13 years at GE Medical Systems, where he held various sales, marketing and strategic management roles.

Augusti received his M.B.A. from UCLA Anderson School of Management, and his B.S. in computer science and economics from Duke University.

Integra makes devices for orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.

Calls to Bioventus to inquire about a replacement or temporary CEOwere not immediately returned.